DrugBank target: Q16671

DrugBank target: Q16671 (AMHR2_HUMAN)     

Anti-Muellerian hormone type-2 receptor

Anti-Muellerian hormone type II receptor, MIS type II receptor, AMH type II receptor, MISRII, MRII.


On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for anti-Muellerian hormone..

Enzyme   [EC->PDB]   [IntEnz]   [ExPASy]   [KEGG]  

Catalytic activity

ATP + [receptor-protein] = ADP + [receptor- protein] phosphate.


Persistent Muellerian duct syndrome 2 (PMDS2) [MIM:261550]: A form of male pseudohermaphroditism characterized by a failure of Muellerian duct regression in otherwise normal males. Note=The disease is caused by mutations affecting the gene represented in this entry.


There are currently no structures for this UniProt code in the PDB.

Schematic diagram of Pfam domains in target sequence

Key:    PfamA domain  PfamB domain

Sequence length: 573 a.a.

Approved nutraceuticals targeting this protein

The DrugBank database identifies 1 nutraceutical for this target protein:


Generic name: DB00171 adenosine triphosphate
Formula: C10H16N5O13P3
Structure: There are 862 PDB structures containing this molecule although none are bound to the above target protein.